I-SPY 2 TRIAL (Breast Cancer) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to analyze biomarker responses to different drug regimens used for people who have HER2- and HER2+ breast cancer. We hope what we learn from the study can help us develop better treatments and figure out which treatment option(s) will be best for breast cancer patients.
Cáncer de mama
¿Quién puede participar en el Estudio?
Adultos de 18 a 90 años que:
- Are diagnosed with HER2+ and HER2- breast cancer
- Have stage II or III disease
For more information about who can join this study, please contact the study team at sam.womack@duke.edu.
¿Qué Implica?
If you choose to join this study, you will get a random assignment to 1 of several different drug regimens for your cancer. These regimens contain experimental drugs, approved drugs, and/or a mix of experimental and approved drugs.
The study team will let you know before you decide to proceed what drug regimens might be assigned to you before you decide to take part. We will keep in touch with you for up to 5 years after you finish your drug regimen in the study.
Detalles del Estudio
